Key result
Redo TAVR and ViV offer safe options for bioprosthetic valve dysfunction pending long-term durability data.
Why the study?
As TAVR expands to younger, lower-risk patients, long-term transcatheter heart valve durability data are lacking and data on redo-TAVR for failed valves are even more limited.
Redo-TAVR is a feasible option for structural valve deterioration of transcatheter heart valves, but requires careful consideration of mechanisms, timing, coronary access, and post-procedure gradients.
Answers are grounded in this paper and cite their sources.
Supports redo-TAVR in selected patients with bioprosthetic dysfunction; leaves open durability, selection, and technique optimization.
As transcatheter aortic valve replacement (TAVR) expands into a younger and lower risk cohort of patients, many important clinical questions are raised, including the one of overall valve durability. Bioprosthetic valve dysfunction (BVD) is a complex clinical issue, of which structural valve deterioration (SVD) is a subcategory. Similar to surgical bioprosthesis, transcatheter heart valves (THVs) can fail over the years however, data on long-term THVs durability is lacking, especially in the lower risk cohort. Surgical explant with open aortic surgery or a second THV, described as redo-TAVR, are feasible options when the first THV fails. However long-term data in these patients is even more limited. Important clinical considerations such as the mechanism(s) of THV dysfunction, the type and timing of the second procedure must be carefully considered. There are also inherently important clinical concerns regarding redo-TAVR, such as coronary access and higher post procedure gradients. In the present keynote lecture, we review the diagnosis of THV dysfunction and transcatheter options available when SVD occurs.
No takes yet. Share an insight, caveat, or question.
Chatfield et al. (2021) conducted a review in Transcatheter aortic valve replacement (TAVR) dysfunction. Redo transcatheter aortic valve replacement (redo-TAVR) and Valve-in-Valve (ViV) was evaluated. Redo transcatheter aortic valve replacement and valve-in-valve procedures are feasible and safe options for treating bioprosthetic valve dysfunction, though long-term durability data is still needed.
Synapse has enriched 10 related papers. Consider them for comparative context: